Table 3.
Treatment and Clinical outcomes of Dedifferentiated/Undifferentiated melanomas
| Case Number | Immunotherapy +/− Target therapy | Cycles of Immunotherapy (n) and duration of target therapy [months] |
Response/Recurrence | Outcome | Follow-up (months) |
|---|---|---|---|---|---|
| 1 | Nivolumab | (8) | PD, perineural spread along mandibular (V3) nerve, with bilateral adrenal metastases | DOD | 35 |
| 2 | Ipilimumab and Nivolumab | (17) | Complete response, no recurrence | AFD | 63 |
| 3 | Ipilimumab and Nivolumab | (14) | Complete response, no recurrence | AFD | 58 |
| 4 | Ipilimumab and Nivolumab | (3) | PD following IO and RT, hemorrhage following rupture of axillary arteries | DOD | 4 |
| 5 | Ipilimumab and Nivolumab | (15) | Complete response, no recurrence | AFD | 81 |
| 6 | Ipilimumab and Nivolumab | (4) | Durable partial response (near complete response), no progression | AWD | 54 |
| 7 | Nivolumab | (21) | Complete response, no recurrence | AFD | 33 |
| 8 | Ipilimumab and Nivolumab | (1) | PD (CNS metastasis, multiple lesions, largest 2.6 cm) | DOD | 3 |
| 9 | Ipilimumab and Nivolumab | (3) | Stable disease, treatment c/b Colitis, pancreatitis, hypophysitis and stroke | AWD | 14 |
| 10 | Nivolumab | (7) | Complete response, no recurrence | AFD | 12 |
| 11 | Pembrolizumab | (3) | Stable disease | AWD | 18 |
| 12 | Pembrolizumab, Nivolumab, then Ipilimumab | (11), (15), then (3) | PD (progression of CNS metastasis; Basal ganglia, 5.8 cm), IO course c/b adrenal insufficiency following bilateral adrenal metastases | DOD | 77 |
| 13 | Dabrafenib and trametinib, then Nivolumab and Ipilimumab | [2], then (1) | Partial response, PD (High burden disease before treatment initiation; metastasis in six organs) | DOD | 6 |
| 14 | Ipilimumab and Nivolumab | (9) | Complete response, no recurrence | AFD | 20 |
| 15 | Ipilimumab and Nivolumab | (23) | Durable Partial response, no progression | AWD | 168 |
| 16 | Pembrolizumab | (10) | Complete response | AFD | 181 |
| 17 | Encorafenib and Binimetinib, then Ipilimumab and Nivolumab | [4], then (1) | Initial good response (50% decrease in splenic metastasis (7.2 to 3.1 cm), IO course c/b worsening dermatomyositis precluding further treatment, PD (brain metastasis – 3 cm) | DOD | 19 |
| 18 | None | n/a | No evidence of disease following resection | AFD | 61 |
| 19 | Ipilimumab and Nivolumab | (5) | Complete response, no recurrence | AFD | 11 |
AFD = Alive and free of disease; AWD = alive with disease; DOD = dead of disease; PD = Progressive disease; M = months; IO = immunotherapy; c/b = complicated by; RT = Radiation therapy; [n] = duration of target therapy in months, (n) = Cycles of immunotherapy.